CN102558013A - (s)- 4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 - Google Patents
(s)- 4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 Download PDFInfo
- Publication number
- CN102558013A CN102558013A CN2011102302445A CN201110230244A CN102558013A CN 102558013 A CN102558013 A CN 102558013A CN 2011102302445 A CN2011102302445 A CN 2011102302445A CN 201110230244 A CN201110230244 A CN 201110230244A CN 102558013 A CN102558013 A CN 102558013A
- Authority
- CN
- China
- Prior art keywords
- oxiracetam
- crystal form
- oxo
- crystal
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 72
- IHLAQQPQKRMGSS-BYPYZUCNSA-N 2-[(4s)-4-hydroxy-2-oxopyrrolidin-1-yl]acetamide Chemical compound NC(=O)CN1C[C@@H](O)CC1=O IHLAQQPQKRMGSS-BYPYZUCNSA-N 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 3
- 229960001227 oxiracetam Drugs 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000012043 crude product Substances 0.000 abstract 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000005260 alpha ray Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
2θ / degree | d / Å | 相对强度I / % |
10.669 | 8.2857 | 9 |
13.25 | 6.6765 | 11 |
13.847 | 6.3903 | 13 |
14.198 | 6.2329 | 21 |
16.729 | 5.2953 | 13 |
17.934 | 4.9422 | 54 |
18.746 | 4.7298 | 33 |
18.816 | 4.7123 | 14 |
20.273 | 4.3769 | 47 |
20.413 | 4.3471 | 58 |
21.431 | 4.1429 | 100 |
21.617 | 4.1077 | 11 |
21.663 | 4.099 | 34 |
23.38 | 3.8018 | 9 |
24.324 | 3.6563 | 11 |
24.415 | 3.6429 | 44 |
26.069 | 3.4154 | 26 |
26.107 | 3.4104 | 40 |
27.901 | 3.1951 | 14 |
28.621 | 3.1164 | 16 |
28.925 | 3.0843 | 13 |
29.449 | 3.0306 | 19 |
29.484 | 3.0271 | 9 |
31.702 | 2.8202 | 26 |
分子式 | C12H22N4O7 |
分子量 | 334.34 |
测试温度 | 150(2) K |
波长 | 1.54178 Å (Cu Kα) |
晶系、空间群 | 正交, P2(1)2(1)2(1) |
晶胞参数 | a = 9.4245(3) Å, α = 90o |
b = 9.4597(3) Å, β = 90o | |
c = 17.3882(6) Å, γ = 90o | |
晶胞体积 | 1550.21(9) Å3 |
Z值,理论密度 | 4, 1.433 g/cm3 |
线性吸收系数 | 1.010 mm-1 |
结构因子F(000) | 712 |
晶体尺寸 | 0.10×0.14×0.10 mm |
数据收集范围θ | 5.09~62.53o |
晶面指标范围 | -10 <= h <= 9, -9 <= k <= 9, -14 <= l <= 19 |
衍射点总数/独立衍射点数目 | 4524/2269 [Rint = 0.0265] |
完整率(θ = 26.00o) | 98.9% |
吸收校正方法 | Ψ-扫描 |
最大/最小透过率 | 0.9058 / 0.8799 |
精修方法 | 基于F2的全矩阵最小二乘法 |
独立衍射点数据/限制/精修参数 | 2421 / 0 /208 |
拟合优度因子GOOF值 | 1.095 |
R因子[I > 2σ(I)]* | R1 =0.0298, wR2 = 0.0697 |
R因子(全部数据) | R1 = 0.0338, wR2 = 0.0730 |
最大残余电子峰/谷 | 0.146 / -0.146 e·A3 |
Claims (5)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110230244 CN102558013B (zh) | 2011-08-11 | 2011-08-11 | (s)- 4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 |
ES12822639.6T ES2609354T3 (es) | 2011-08-11 | 2012-04-24 | Forma cristalina II de (S)-4-hidroxi-2-oxo-1-pirrolidina acetamida y método de preparación de la misma |
PCT/CN2012/074582 WO2013020391A1 (zh) | 2011-08-11 | 2012-04-24 | (s)-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 |
EP12822639.6A EP2743260B1 (en) | 2011-08-11 | 2012-04-24 | Crystal form ii of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide and preparation method thereof |
US14/237,894 US9126929B2 (en) | 2011-08-11 | 2012-04-24 | (S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide racemate crystal form II and preparation method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110230244 CN102558013B (zh) | 2011-08-11 | 2011-08-11 | (s)- 4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102558013A true CN102558013A (zh) | 2012-07-11 |
CN102558013B CN102558013B (zh) | 2013-12-18 |
Family
ID=46404781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110230244 Active CN102558013B (zh) | 2011-08-11 | 2011-08-11 | (s)- 4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9126929B2 (zh) |
EP (1) | EP2743260B1 (zh) |
CN (1) | CN102558013B (zh) |
ES (1) | ES2609354T3 (zh) |
WO (1) | WO2013020391A1 (zh) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103553997A (zh) * | 2013-11-06 | 2014-02-05 | 重庆润泽医药有限公司 | 一种(s)-奥拉西坦晶型iii的制备方法 |
CN104370792A (zh) * | 2013-08-13 | 2015-02-25 | 天津汉瑞药业有限公司 | 奥拉西坦化合物 |
WO2015067130A1 (zh) | 2013-11-06 | 2015-05-14 | 重庆润泽医药有限公司 | (s)-奥拉西坦晶型iii及其制备方法和用途 |
CN107011234A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | 熔融法制备左旋奥拉西坦晶型ii的方法 |
CN107011231A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | S-奥拉西坦晶型i的制备方法 |
CN107011230A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | pH法制备左旋奥拉西坦晶型II的方法 |
CN107011232A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | 球磨制备左旋奥拉西坦晶型ii的方法 |
CN107021901A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | (s)-奥拉西坦晶型ii的制备方法 |
CN107021908A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107021897A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种制备左旋奥拉西坦晶型ii的方法 |
CN107021899A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种制备左旋奥拉西坦晶型ii的方法 |
CN107021905A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107021898A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种球磨法制备左旋奥拉西坦晶型ii的方法 |
CN107021900A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种(s)-奥拉西坦晶型ii的制备方法 |
CN107021906A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107021911A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种制备左旋奥拉西坦晶型ii的方法 |
CN107021896A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦晶型ii的制备方法 |
CN107021909A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦晶型ii的制备方法 |
CN107021904A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107021910A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备s-奥拉西坦晶型ii的方法 |
CN107021907A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 左旋奥拉西坦晶型ii的制备方法 |
CN107021914A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 左旋奥拉西坦晶型ii的制备方法 |
CN108567750A (zh) * | 2017-03-14 | 2018-09-25 | 重庆润泽医药有限公司 | 左旋羟氧吡醋胺药物组合物及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102531988A (zh) * | 2011-08-11 | 2012-07-04 | 重庆润泽医疗器械有限公司 | 一种左旋奥拉西坦的纯化方法 |
CN102531989B (zh) * | 2011-08-11 | 2014-02-05 | 重庆润泽医药有限公司 | 一种(s)-奥拉西坦的纯化方法 |
EP3530271A4 (en) * | 2016-10-24 | 2020-03-25 | Chongqing Runze Pharmaceutical Company Limited | CRYSTALLINE FORM II OF DEXTRAL-OXIRACETAM, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1956953A (zh) * | 2004-05-25 | 2007-05-02 | 安国药品株式会社 | 旋光纯4-羟基-2-氧化-1-吡咯烷乙酰胺的制备方法 |
CN101367757A (zh) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
CN101575309A (zh) * | 2009-04-28 | 2009-11-11 | 中国医药集团总公司四川抗菌素工业研究所 | 合成(s)-奥拉西坦的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9121289D0 (en) | 1991-10-08 | 1991-11-20 | Isf Spa | Composition and use |
CN1268611C (zh) | 2002-06-22 | 2006-08-09 | 张家港浩波化学品有限公司 | 制备4-羟基吡咯烷酮-2-乙酰胺的方法 |
CN1424034A (zh) | 2002-12-03 | 2003-06-18 | 诸葛华明 | 一种奥拉西坦注射液制剂的制备方法及制品 |
CN1555794A (zh) | 2004-01-02 | 2004-12-22 | 肖广常 | 奥拉西坦分散片及其制备方法 |
CN1562000A (zh) | 2004-03-23 | 2005-01-12 | 天津市资福医药科技开发有限公司 | 4-羟基-2-氧代-1-吡咯烷乙酰胺冻干制剂及其制备方法 |
CN1948285A (zh) | 2006-10-31 | 2007-04-18 | 张家港浩波化学品有限公司 | 制备4-羟基吡咯烷酮-2-乙酰胺的方法 |
CN100593403C (zh) | 2007-08-31 | 2010-03-10 | 石药集团欧意药业有限公司 | 奥拉西坦制剂及制备方法 |
CN101121688A (zh) | 2007-09-14 | 2008-02-13 | 南开大学 | 合成奥拉西坦的改进方法 |
CN102101836A (zh) * | 2009-12-16 | 2011-06-22 | 北京润德康医药技术有限公司 | S-奥拉西坦新晶型及其制备方法 |
US9238622B2 (en) * | 2010-05-21 | 2016-01-19 | Chongqing Runze Pharmaceutical Co., Ltd. | Crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparing method and use thereof |
CN102531988A (zh) * | 2011-08-11 | 2012-07-04 | 重庆润泽医疗器械有限公司 | 一种左旋奥拉西坦的纯化方法 |
CN102531989B (zh) * | 2011-08-11 | 2014-02-05 | 重庆润泽医药有限公司 | 一种(s)-奥拉西坦的纯化方法 |
CN103342673B (zh) * | 2013-07-31 | 2015-11-18 | 石药集团欧意药业有限公司 | 一种奥拉西坦晶型及其制备方法 |
-
2011
- 2011-08-11 CN CN 201110230244 patent/CN102558013B/zh active Active
-
2012
- 2012-04-24 US US14/237,894 patent/US9126929B2/en active Active
- 2012-04-24 ES ES12822639.6T patent/ES2609354T3/es active Active
- 2012-04-24 WO PCT/CN2012/074582 patent/WO2013020391A1/zh active Application Filing
- 2012-04-24 EP EP12822639.6A patent/EP2743260B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1956953A (zh) * | 2004-05-25 | 2007-05-02 | 安国药品株式会社 | 旋光纯4-羟基-2-氧化-1-吡咯烷乙酰胺的制备方法 |
CN101367757A (zh) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
CN101575309A (zh) * | 2009-04-28 | 2009-11-11 | 中国医药集团总公司四川抗菌素工业研究所 | 合成(s)-奥拉西坦的方法 |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104370792A (zh) * | 2013-08-13 | 2015-02-25 | 天津汉瑞药业有限公司 | 奥拉西坦化合物 |
CN104370792B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 奥拉西坦化合物 |
CN103553997A (zh) * | 2013-11-06 | 2014-02-05 | 重庆润泽医药有限公司 | 一种(s)-奥拉西坦晶型iii的制备方法 |
WO2015067130A1 (zh) | 2013-11-06 | 2015-05-14 | 重庆润泽医药有限公司 | (s)-奥拉西坦晶型iii及其制备方法和用途 |
CN103553997B (zh) * | 2013-11-06 | 2015-11-25 | 温州智创科技有限公司 | 一种(s)-奥拉西坦晶型iii的制备方法 |
US9670156B2 (en) | 2013-11-06 | 2017-06-06 | Chongqing Ruzer Pharmaceutical Company Limited | Crystal form III of (S)-oxiracetam, preparation method and use thereof |
CN107021897A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种制备左旋奥拉西坦晶型ii的方法 |
CN107021898A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种球磨法制备左旋奥拉西坦晶型ii的方法 |
CN107011230A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | pH法制备左旋奥拉西坦晶型II的方法 |
CN107011232A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | 球磨制备左旋奥拉西坦晶型ii的方法 |
CN107021901A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | (s)-奥拉西坦晶型ii的制备方法 |
CN107021908A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107011234A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | 熔融法制备左旋奥拉西坦晶型ii的方法 |
CN107021899A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种制备左旋奥拉西坦晶型ii的方法 |
CN107021905A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107011231A (zh) * | 2016-01-29 | 2017-08-04 | 重庆润泽医药有限公司 | S-奥拉西坦晶型i的制备方法 |
CN107021900A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种(s)-奥拉西坦晶型ii的制备方法 |
CN107021906A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107021911A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种制备左旋奥拉西坦晶型ii的方法 |
CN107021896A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦晶型ii的制备方法 |
CN107021909A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦晶型ii的制备方法 |
CN107021904A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备左旋奥拉西坦晶型ii的方法 |
CN107021910A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 制备s-奥拉西坦晶型ii的方法 |
CN107021907A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 左旋奥拉西坦晶型ii的制备方法 |
CN107021914A (zh) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | 左旋奥拉西坦晶型ii的制备方法 |
CN108567750A (zh) * | 2017-03-14 | 2018-09-25 | 重庆润泽医药有限公司 | 左旋羟氧吡醋胺药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2609354T3 (es) | 2017-04-19 |
CN102558013B (zh) | 2013-12-18 |
EP2743260A4 (en) | 2015-01-07 |
US9126929B2 (en) | 2015-09-08 |
WO2013020391A1 (zh) | 2013-02-14 |
US20140235871A1 (en) | 2014-08-21 |
EP2743260A1 (en) | 2014-06-18 |
EP2743260B1 (en) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102558013B (zh) | (s)- 4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅱ及其制备方法 | |
KR101888215B1 (ko) | L-오르니틴 페닐아세테이트의 제조 방법 | |
US9126928B2 (en) | 4-hydroxy-2-oxo-1-pyrrolidineacetamide racemate crystal form I and preparation method therefor | |
JP2013541592A5 (zh) | ||
JP7031002B2 (ja) | ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法 | |
CN108047151A (zh) | 一种高收率钆布醇的制备方法 | |
CN102702008B (zh) | 阿戈美拉汀硫酸复合物及其制备方法 | |
JP2013531643A (ja) | 結晶質3,6,9−トリアザ−3,6,9−トリス(カルボキシメチル)−4−(4−エトキシベンジル)ウンデカン二酸を調製する方法及びプリモビスト(Primovist)(登録商標)を製造するための方法 | |
CN104610195B (zh) | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 | |
CN104557881B (zh) | 一种盐酸帕唑帕尼晶型的制备方法 | |
CN105175355B (zh) | 一种2-氰基吩噻嗪的制备方法 | |
JP2018104312A (ja) | イミダゾピロロキノリン塩及びその製造方法、並びに、医薬品、化粧品及び食品 | |
Beraldo et al. | Structural studies and spectral characteristics of 4-benzoylpyridine thiosemicarbazone and N (4′)-phenyl-4-benzoylpyridine thiosemicarbazone | |
CN105218433A (zh) | 一种琥珀酸多西拉敏新晶型及其制备方法和应用 | |
CN108864063A (zh) | 一种治疗癌症的药物溶剂合物及其制备方法 | |
CN104177271A (zh) | 一种氯化乙酰左卡尼汀的制备方法 | |
CN105985252B (zh) | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 | |
CN110256375B (zh) | 一种甲灭酸-哌嗪盐型及其制备方法 | |
Davidovich et al. | Monomeric complex [HfF 5 (H 2 O) 2]− anion in the crystal structure of 4-amino-1, 2, 4-triazolium pentafluorohafnate trihydrate: Synthesis and X-ray study | |
CN107663193A (zh) | 盐酸帕唑帕尼及其制备方法和用途 | |
CN108892677B (zh) | 一种头孢地尼的粒度控制方法 | |
JPWO2017086447A1 (ja) | 3−ヒドロキシイソ吉草酸の一価カチオン塩の結晶および該結晶の製造方法 | |
CN103772298A (zh) | 一种盐酸厄罗替尼多晶型物及其制备方法 | |
TWI693209B (zh) | 沙庫比曲鈉鹽製備方法及其應用 | |
CN106748819A (zh) | 沙丁胺醇苯甲酸盐的制备方法及其晶体结构 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 401120 Chongqing city Yubei District Shuangfeng Bridge Street Airport Road No. 296 Building 1 yuan and 7 2- store Applicant before: Chongqing Runze Medical Instruments Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING RUNZE MEDICAL INSTRUMENTS LTD. TO: CHONGQING RUNZE PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHONGQING DONGZE PHARMACEUTICAL TECHNOLOGY DEVELOP Free format text: FORMER OWNER: CHONGQING RUNZE PHARMACEUTICAL CO., LTD. Effective date: 20140312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400042 YUBEI, CHONGQING TO: 400030 SHAPINGBA, CHONGQING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140312 Address after: 400030 Chongqing city Shapingba District Yubei Road No. 50 of No. 13-15-6A Patentee after: DONGZE PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. Address before: 400042 Chongqing city Yubei District Qinye Road No. 9 Patentee before: Chongqing Runze Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170825 Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Patentee after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 400030 Chongqing city Shapingba District Yubei Road No. 50 of No. 13-15-6A Patentee before: DONGZE PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. |
|
TR01 | Transfer of patent right |